Anti-vascular endothelial growth factor in glioblastoma: a systematic review and meta-analysis

Xiao, Qin; Yang, Shaodong; Ding, Guanfu; Luo, Muyun

doi:10.1007/s10072-018-3568-y

Cited by 16 publications

(24 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, PTEN is a key negative regulator of the PI3K/Akt pathway (Stambolic et al, 1998; Cantley and Neel, 1999). In addition, gliomas display the upregulation of angiogenic factors, such as the FGF (fibroblast growth factor), TGF (transforming growth factor), Interleukin 8 (IL-8), and Vascular-Endothelial Growth Factor (VEGF) (Benoy et al, 2004; Slettenaar and Wilson, 2006; Xiao et al, 2018). The combination of the genetic alteration of these factors triggers a malignant glioma with an aggressive phenotype and that is resistant to intensive therapies.…”

Section: Gliomasmentioning

confidence: 99%

Theranostic Nanomedicine for Malignant Gliomas

d’Angelo

Castelli

Benedetti

et al. 2019

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Brain tumors mainly originate from glial cells and are classified as gliomas. Malignant gliomas represent an incurable disease; indeed, after surgery and chemotherapy, recurrence appears within a few months, and mortality has remained high in the last decades. This is mainly due to the heterogeneity of malignant gliomas, indicating that a single therapy is not effective for all patients. In this regard, the advent of theranostic nanomedicine, a combination of imaging and therapeutic agents, represents a strategic tool for the management of malignant brain tumors, allowing for the detection of therapies that are specific to the single patient and avoiding overdosing the non-responders. Here, recent theranostic nanomedicine approaches for glioma therapy are described.

show abstract

Section: Gliomasmentioning

confidence: 99%

Theranostic Nanomedicine for Malignant Gliomas

d’Angelo

Castelli

Benedetti

et al. 2019

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Zhu et al proved that systemic administration of neutralizing anti-CCL2 mAbs can block recruitment and decrease the number of MDSCs in the TME, providing significant survival benefits in mouse GL261 glioma and human U87 glioma xenograft models (112). Chen et al reported that anti-VEGF antibody can effectively decrease the recruitment of MDSCs to tumor tissue (113), while anti-VEGF treatment has been proposed to enhance the survival and quality of life in glioma patients (114,115). Many studies proved the protective effect of COX-2 inhibitors on glioma (116,117), and the use of non-steroidal anti-inflammatory drugs was significantly associated with a lower risk of glioma (118,119).…”

Section: Inhibition Of Mdsc Migration and Expansionmentioning

confidence: 99%

The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment

Guo

Luan

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid progenitor and precursor cells at different stages of differentiation, which play an important role in tumor immunosuppression. Glioma is the most common and deadliest primary malignant tumor of the brain, and ample evidence supports key contributions of MDSCs to the immunosuppressive tumor microenvironment, which is a key factor stimulating glioma progression. In this review, we summarize the source and characterization of MDSCs, discuss their immunosuppressive functions, and current approaches that target MDSCs for tumor control. Overall, the review provides insights into the roles of MDSC immunosuppression in the glioma microenvironment and suggests that MDSC control is a powerful cellular therapeutic target for currently incurable glioma tumors.

show abstract

“…Only one agent, the anti-VEGF antibody bevacizumab, has shown some efficacy in controlled clinical trials so far. This efficacy is, however, limited to improve progression-free survival (PFS) but not the overall survival in patients affected by primary and recurrent glioblastoma [ 202 ]. Targeting specific pathways either by extracellular receptor binding or affecting downstream targets, such as small tyrosine kinase molecules has also been an emerging therapeutic option.…”

Section: Current Treatments and Future Therapymentioning

confidence: 99%

Advances in Research of Adult Gliomas

Finch

Solomou

Wykes

et al. 2021

IJMS

View full text Add to dashboard Cite

Diffuse gliomas are the most frequent brain tumours, representing 75% of all primary malignant brain tumours in adults. Because of their locally aggressive behaviour and the fact that they cannot be cured by current therapies, they represent one of the most devastating cancers. The present review summarises recent advances in our understanding of glioma development and progression by use of various in vitro and in vivo models, as well as more complex techniques including cultures of 3D organoids and organotypic slices. We discuss the progress that has been made in understanding glioma heterogeneity, alteration in gene expression and DNA methylation, as well as advances in various in silico models. Lastly current treatment options and future clinical trials, which aim to improve early diagnosis and disease monitoring, are also discussed.

show abstract

Anti-vascular endothelial growth factor in glioblastoma: a systematic review and meta-analysis

Cited by 16 publications

References 29 publications

Theranostic Nanomedicine for Malignant Gliomas

Theranostic Nanomedicine for Malignant Gliomas

The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment

Advances in Research of Adult Gliomas

Contact Info

Product

Resources

About